Boston Life Sciences To Host 2006 4th Quarter Conference Call
March 29 2007 - 11:45AM
PR Newswire (US)
HOPKINTON, Mass., March 29 /PRNewswire-FirstCall/ -- Boston Life
Sciences, Inc. (NASDAQ:BLSI) today announced that they will host a
conference call on Tuesday, April 3, 2007 at 10:30am EDT to review
the fourth quarter of 2006 and discuss other matters related to the
Company. To access the conference call, please dial (800) 262-1292
for domestic and (719) 457-2681 international. The code for this
conference call is 3944552. Please dial in 5 to 10 minutes prior to
the scheduled start time. A replay of the call will be posted on
the Investor Relations section of the website,
http://www.bostonlifesciences.com/, within 48 hours following the
conference call and will be available through Tuesday, April 17,
2007. About Boston Life Sciences, Inc. Boston Life Sciences, Inc.
(BLSI) is engaged in the research and clinical development of
diagnostic and therapeutic products for central nervous system
(CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase
III clinical trials for the diagnosis of Parkinson's Disease (PD)
and Phase II clinical trials for the diagnosis of Attention Deficit
Hyperactivity Disorder (ADHD). Cethrin(R), a
recombinant-protein-based drug designed to promote nerve repair
after acute spinal cord injury, has reported positive interim
results in a North American Phase I/IIa clinical trial. The
company's research and pre- clinical CNS programs include Inosine
for the treatment of spinal cord injury and stroke, a DAT blocker
for the treatment of Parkinson's disease, and a second generation
technetium-based molecular imaging agent for PD and ADHD. BLSI's
current research collaborations include Harvard Medical School,
University of Montreal and Children's Hospital Boston. Safe Harbor
The foregoing release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward- looking statements include statements regarding
Boston Life Sciences' future expectations, beliefs, intentions,
goals, strategies, plans or prospects regarding the future,
including the development and commercialization of ALTROPANE and
Cethrin, the prospects of the Company's CNS therapeutics program,
the Company's strategies to develop and commercialize axon
regeneration technologies and the breadth of the Company's
technologies and intellectual property portfolio. Forward-looking
statements can be identified by terminology such as "anticipate,"
"believe," "could," "could increase the likelihood," "estimate,"
"expect," "intend," "is planned," "may," "should," "will," "will
enable," "would be expected," "look forward," "may provide,"
"would" or similar terms, variations of such terms or the negative
of those terms. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors including those
risks, uncertainties and factors referred to in the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2006 filed with the Securities and Exchange Commission under the
section "Risk Factors," as well as other documents that may be
filed by Boston Life Sciences from time to time with the Securities
and Exchange Commission. As a result of such risks, uncertainties
and factors, the Company's actual results may differ materially
from any future results, performance or achievements discussed in
or implied by the forward-looking statements contained herein.
Boston Life Sciences is providing the information in this press
release as of this date and assumes no obligations to update the
information in this press release. Contact: Meredith Patin --
508-497-2360 ext 239 Boston Life Sciences, Inc. DATASOURCE: Boston
Life Sciences, Inc. CONTACT: Meredith Patin of Boston Life
Sciences, Inc., +1-508-497-2360 ext 239, Web site:
http://www.bostonlifesciences.com/
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Apr 2023 to Apr 2024